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Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) is regarded
a relatively mild leukodystrophy, diagnosed by characteristic long tract abnormalities on MRI and biallelic
variants inDARS2, encodingmitochondrial aspartyl-tRNA synthetase (mtAspRS).DARS2 variants in LBSL
are almost invariably compound heterozygous; in 95% of cases, 1 is a leaky splice site variant in intron 2. A
few severely affected patients, still fulfilling theMRI criteria, have been described.We noticed highly unusual
MRI presentations in 15 cases diagnosed by WES. We examined these cases to determine whether they
represent consistent novel LBSL phenotypes.
Methods
We reviewed clinical features, MRI abnormalities, and gene variants and investigated the variants’ impact
on mtAspRS structure and mitochondrial function.
Results
We found 2 MRI phenotypes: early severe cerebral hypoplasia/atrophy (9 patients, group 1) and white
matter abnormalities without long tract involvement (6 patients, group 2). With antenatal onset, micro-
cephaly, and arrested development, group 1 patients were most severely affected. DARS2 variants were
severer than for classic LBSL and severer for group 1 than group 2. All missense variants hit mtAspRS regions
involved in tRNAAsp binding, aspartyl-adenosine-59-monophosphate binding, and/or homodimerization.
Missense variants expressed in the yeast DARS2 ortholog showed severely affected mitochondrial function.
Conclusions
DARS2 variants are associated with highly heterogeneous phenotypes. New MRI presentations are
profound cerebral hypoplasia/atrophy and white matter abnormalities without long tract involvement.
Our findings have implications for diagnosis and understanding disease mechanisms, pointing at dom-
inant neuronal/axonal involvement in severe cases. In line with this conclusion, activation of biallelic
DARS2 null alleles in conditional transgenic mice leads to massive neuronal apoptosis.
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Leukoencephalopathy with brainstem and spinal cord in-
volvement and lactate elevation (LBSL, MIM 611105) was
identified in 2003 as a distinct leukodystrophy based on a highly
characteristic MRI pattern with signal abnormalities in the
periventricular and deep cerebral whitematter, posterior limb of
the internal capsule, and specific brain stem and spinal cord
tracts.1 Diagnostic MRI criteria were established in 2007 and
revised in 2012.2,3 LBSL typically has a relatively mild disease
course with childhood or adolescent onset and slowly pro-
gressive pyramidal, cerebellar, and dorsal column dysfunction.1,4
The clinical spectrum is, however, broad, ranging from severely
affected neonatal-onset cases with early demise to oligo-
symptomatic adult-onset cases with normal life span.3–6 So far,
almost all published LBSL cases fulfill the MRI criteria, also
patients at the extreme ends of the clinical spectrum.2–4
LBSL is caused by recessive variants inDARS2 (MIM610956).2
DARS2 encodes mitochondrial aspartyl-tRNA synthetase
(mtAspRS), which is necessary for the translation of the mito-
chondrial genome.2 Almost all published cases have compound
heterozygous DARS2 variants; 95% of the cases have 1 splice
site variant at the 39-end of intron 2.4 The leaky nature of these
splice site variants ensures some residual protein function.7
We recently noticed highly unusual MRI presentations in
several patients with biallelic DARS2 variants diagnosed by
whole-exome sequencing (WES). We reviewed clinical fea-
tures, MRI abnormalities, and gene variants systematically and
investigated the impact of the variants on mitochondrial
function to determine whether the patients represent con-
sistent novel LBSL phenotypes.
Methods
Standard Protocol Approvals and
Patient Consents
The study was approved by the ethics committee of the
Amsterdam University Medical Centers, location VU Univer-
sity Medical Center; written informed consent was obtained
from guardians of participating patients. Patients with DARS2
variants and unusually severe and atypical MRI abnormalities
were included. Clinical information was derived from clinical
questionnaires for physicians and medical records.
MRIs
The first and, if performed, last MRI of each patient was
analyzed by 2 observers (M.D.S. and M.S.v.d.K.) using a
standardized protocol.8 The MRIs had been performed for
diagnostic purposes in different centers between 2007 and
2018. Sagittal T1- and transverse T2-weighted images were
available in all patients. As different spectroscopy protocols had
been used, only presence or absence of lactate was assessed.
DARS2Variants: Interpretation andMapping on
Crystal Structure
The DARS2 variants were identified by clinical WES. Their
pathogenic role on protein function (SIFT, PolyPhen, and
RUSSELL score) was predicted using Alamut Visual version
2.9 (Interactive Biosoftware, Rouen, France) andMechismo.9
Combinations of variants were compared with previously
published data.4
The effects of missense variants on the protein function were
analyzed based on the crystal structure of homodimeric hu-
man mtAspRS (Protein Data Bank [PDB] entry 4AH6). We
used crystal complexes of bacterial AspRS with tRNAAsp and
aspartyl-adenosine-59-monophosphate (PDB 1EFW and
1G51) to model the binding of these functional ligands on the
human homodimeric mtAspRS structure. These ligands were
assumed to conserve their binding mode, as human and
bacterial orthologs present essentially the same fold.
To determine whether the missense variants affect the local
protein structure, we calculated the folding free energy changes
(DDG) associated with the amino acid replacements in the
homodimeric humanmtAspRS crystal structure using FoldX.10
To check reliability, DDG values were compared with those
calculated on corresponding variants in a homodimeric bacte-
rial AspRS structure (PDB 1L0W), which has a better atomic
resolution (2.01Å vs the 3.7Å of the human protein structure).
The average of 5 independent DDG calculations is shown for
each missense variant. ADDG value significantly different from
zero indicates structural alterations and possible pathogenicity,
but DDG values alone cannot provide a severity grade.
To clarify the pathogenic effects of variants, the knowledge of
structural effects based on DDG calculations, residue con-
servation, and structural/functional role of the affected amino
acids was combined, taking into account their proximity to
functional regions, such as ligand binding and catalysis.
Yeast Methods
Strains, Plasmids, and Media
Yeast strains were derived fromW303‐1B (Matα ade2-1 leu2-3,
112 ura3-1 trp1-1 his3-11, and 15 can1-100) and grown in
Glossary
ADC = apparent diffusion coefficient; LBSL = Leukoencephalopathy with brainstem and spinal cord involvement and lactate
elevation; mtAspRS = mitochondrial Aspartyl tRNA synthetase; PDB = Protein Data Bank; SC = synthetic complete;WES =
whole-exome sequencing.
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synthetic complete (SC) media (0.69% yeast nitrogen base
without amino acids, FormediumTM, United Kingdom), sup-
plemented with 1 g/L dropout mix, which includes amino acids
and bases except for those necessary to keep the plasmids
(i.e., uracil for vector pFL38 and tryptophan for vector
pFL39).11 Media were supplemented with various carbon
sources at 2% (weight/volume) (Carlo Erba Reagents).
The yeast DARS2 ortholog MSD1 and its natural promoter
were cloned into the pFL38 vector.12 In addition, the HA-tag
was cloned at the 39 end of the MSD1 allele. The resulting
plasmids, pFL38MSD1 and pFL38MSD1HA, were in-
troduced into the W303‐1B strain.13
The endogenous MSD1 gene was disrupted in the W303-1B
strains harboring pFL38MSD1 or pFL38MSD1HA through
one-step gene disruption,14 obtaining W303-1B msd1D/
pFL38MSD1 and W303-1B msd1D/pFL38MSD1HA. After
verifying that the HA-tag did not affect the respiratory
growth phenotype (data not shown),MSD1HA was cloned
from pFL38 to pFL39 and mutagenized by site-directed
mutagenesis (Stratagene, La Jolla, CA).12 Cloned se-
quences were verified by Sanger sequencing. The vectors
containing the mutant or humanized alleles were trans-
formed into msd1D/pFL38MSD1. The pFL38‐MSD1 was
lost through plasmid‐shuffling on 5-fluoroorotic acid
(5FOA)-containing medium.
Functional Analyses
The oxidative growth ability was assessed as before.15 Yeast
was grown on SC agar plates (without tryptophan) supple-
mented with 2% glucose or 2% ethanol. Plates were incubated
at 28 or 37°C, and growth was visually scored after 3 days.
Oxygen consumption rate was measured, as described.15
Protein Extraction and Western Blot Analysis
Total protein was extracted from 10 OD600 cells grown in the
same growth conditions used for measurement of respiratory
activity.16 Protein pellets were suspended in 150 μL Laemmli
sample buffer. Equal volumes (15 μL) were subjected to SDS-
PAGE; electro-blottedmembranes were incubated with rat anti-
HA (Sigma-Aldrich, 1:2000) and mouse anti-Por1 (Abcam, 1:
10,000) antibodies and subsequently with anti-rat DyLight 650
(Thermo Fisher Scientific, 1:4,000) and anti-mouse StarBright
Blue520 (Bio-Rad, 1:10,000) secondary antibodies. Fluores-
cence signals were measured with Bio-Rad ChemiDoc Imagers
and analyzed with Image Lab Software (Bio-Rad).
Data Availability
Anonymized data will be shared by request from any qualified
investigator.
Results
Patients and Clinical Features
Fifteen patients were included (2 males and 13 females). Two
different MRI phenotypes were distinguished, and patients
were divided accordingly: group 1 characterized by severe
cerebral atrophy (9 patients) and group 2 by severe cerebral
white matter abnormalities (6 patients). Table 1 and table e-1,
links.lww.com/NXG/A376, provide summarized and detailed
clinical information, respectively.
In group 1, age at onset ranged from antenatal to 3 months
after birth. Almost all patients had microcephaly at birth, in-
dicative of antenatal disease onset. All patients had severe
microcephaly at latest examination. One patient (LBSL285)
had tachypnea due to metabolic acidosis in the neonatal pe-
riod. In the case of postnatal onset, no preceding events were
reported. Most did not develop eye contact or lost it soon
after birth. They reached (almost) no motor milestones and
no speech. Most developed epilepsy. Only patient LBSL284
had a somewhat better development and could make a few
steps with maximum support. Patient LBSL285 died at almost
4 years due to respiratory failure. The oldest patient is now 13
years.
In group 2, age at onset ranged from 2months to 2 years. Only
1 patient (LBSL297) developed microcephaly at follow-up.
Three patients achieved walking without support. Two pa-
tients showed slow improvement and 4 deteriorated. Only 1
patient (LBSL280) developed severe epilepsy, lost eye con-
tact and all motor milestones, and died at age 2 years. The
oldest patient is now 11 years.
MRIs
Table 2 and table e-2, links.lww.com/NXG/A376, provide
summarized and detailed findings of the 22 available MRIs,
respectively.
For group 1, MRIs of patient LBSL285 can be regarded as
prototype and are described in more detail (figure 1). The
first MRI was obtained 2 days after birth. The cerebral
hemispheres were small, appearing hypoplastic, but the skull
was larger, suggesting also atrophy. Subdural effusions filled
the space between brain and skull. Numerous abnormal,
tortuous blood vessels were present at the brain surface. The
cerebral cortex had abnormal signal intensity and appeared
thin. The corpus callosum was extremely thin. The posterior
limb of the internal capsule, middle and inferior cerebellar
peduncles, and pyramidal tracts in the midbrain, pons, and
medulla were T2 hyperintense. Restricted diffusion was
present in the entire cerebral cortex, posterior limb of the
internal capsule, cerebellar white matter, brain stem, and
spinal cord, but not in the cerebral hemispheric white matter.
Repeat MRI at 5 months revealed that the cerebral mantle
was reduced to a thin rim. In the frontal region, the cortex
and white matter were still distinguishable and both thin.
The posterior horns of the ventricles were highly dilated.
The size of the basal ganglia, brain stem, and cerebellum was
relatively preserved; the thalamus had become small. The
abnormal blood vessels had largely disappeared. Many white
matter tracts were abnormal in signal. Diffusion restriction
was present in the central cerebral white matter, posterior
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limbs of the internal capsule, inferior cerebellar peduncles,
and pyramids.
Most patients in group 1 shared these MRI characteristics.
They had severe cerebral hypoplasia and progressive atrophy
on sequential MRIs. Subdural effusions were present in 4
patients. Numerous tortuous vessels were seen at the brain
surface on early MRIs. LBSL281 and LBSL294 also displayed
restricted diffusion in the cerebral cortex. Almost all patients
had restricted diffusion in affected white matter tracts. MR
spectroscopy revealed elevated white matter lactate in 1 of 2
patients. TheMRI of LBSL284 at 3.9 years shared the cerebral
Table 1 Summary of Clinical Features
Clinical features Group 1 (n = 9) Group 2 (n = 6)
History
Sex (male/female) 1/8 1/5
Consanguinity parents 0/9 (0%) 0/5 (0%)
Abnormal pregnancy or delivery, other than microcephaly 2/9 (22%) 1/6 (17%)
Microcephaly at birth 6/8 (75%) 0/5 (0%)
Abnormal neonatal period, other than microcephaly 7/9 (78%) 0/6 (0%)
Age at first signs (range), other than microcephaly At birth – 3 mo 2 mo–2 y
No major milestones 6/9 (67%) 0/6 (0%)
Delayed major milestones 3/9 (33%) 2/6 (33%)
Unsupported walking 0/9 (0%) 3/6 (50%)
Provoking factors 0/9 (0%) 5/5 (100%, i.e., fever or trauma)
Last examination
Tube feeding 6/9 (67%) 1/5 (20%)
Microcephaly 9/9 (100%) 1/6 (17%)
Unsupported walking 0/9 (0%) 2/6 (33%)
Epileptic seizures 7/9 (78%) 2/5 (40%)
Eye contact 0/9 (0%) 4/5 (80%)
Able to speak 0/9 (0%) 2/5 (40%)
Truncal hypotonia 9/9 (100%) 3/5 (60%)
Spasticity 9/9 (100%) 4/5 (80%)
Ataxia Not evaluable 2/4 (50%)
Death 1/9 (11%) 1/5 (20%)
Table 2 Summary of MRI Features
MRI features Group 1 (n = 9) Group 2 (n = 6)
Tortuous vessels 6/9 (67%) 0/6 (0%)
Cerebral hypoplasia and atrophy 9/9 (100%) 0/6 (0%)
Diffusion restriction cerebral cortex 3/9 (33%) 0/4 (0%)
Rarefied or cystic cerebral white matter 1/8 (13%) 6/6 (100%)
Diffusion restriction abnormal white matter 7/9 (78%) 4/4 (100%)
SA brain stem tracts 4/9 (44%) 1/6 (17%)
Abbreviation: SA = signal abnormality.
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atrophy but lacked all other abnormalities; no earlier MRI was
available.
For group 2, MRIs of patient LBSL288 can be regarded as
prototype (figure 2). The first MRI was obtained at 1.2 years.
The deep cerebral white matter was homogeneously and
symmetrically abnormal in signal; periventricular and sub-
cortical rims were spared. FLAIR images revealed rarefaction
of part of the abnormal cerebral white matter. The middle
blade of the corpus callosum was affected; thin inner and
outer blades were spared. The splenium was swollen and
rarefied; the isthmus was less severely affected. Other struc-
tures with an abnormal signal intensity included posterior
limbs of the internal capsule, middle cerebellar peduncles, and
central cerebellar white matter. The brain stem and the spinal
cord were spared. The cerebral white matter contained several
small areas of contrast enhancement. MR spectroscopy
showed highly elevated white matter lactate. Diffusion re-
striction with low apparent diffusion coefficient (ADC) values
was present in the deep cerebral white matter, surrounding
rarefied regions. On follow-up MRI at 8.2 years, the cerebral
white matter became more rarefied and cystic. No contrast
enhancement was seen. Restricted diffusion remained present
in nonrarefied abnormal white matter. The corpus callosum
had become atrophic. The brain stem and cervical spinal cord
remained unaffected.
Patients in group 2 shared most MRI characteristics. Rar-
efaction of abnormal cerebral white matter and in-
volvement of the middle blade of the corpus callosum with
sparing of inner and outer blades were common features.
No contrast enhancement was observed. Strikingly, all
patients, except LBSL280, lacked brain stem abnormalities
typical of LBSL, whereas only 3 of 5 patients had long tract
Figure 1 Prototype MRI for Group 1
In patient LBSL285 at age 2 days, the cerebrum is
hypoplastic (A and B). Numerous abnormal, tor-
tuous blood vessels are seen at the surface (B).
The cortex is hardly discernible from the white
matter (B). Diffusion restriction is present in the
cerebral cortex (diffusion-weighted image in D,
ADC map in E). Tracts in the brainstem are af-
fected; shown are the pyramids and inferior
cerebellar peduncles (C), which also display dif-
fusion restriction (F). On follow-up at 5 months,
the cerebral mantle is reduced to a thin rim
(G and H). The abnormal vessels are no longer
visible (H). The pyramids and inferior cerebellar
peduncles are still abnormal (I). Diffusion re-
striction is shown in the posterior limb of the
internal capsule, cerebellar white matter, and
brain stem tracts (diffusion-weighted images in J
and L; ADC map in K).
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involvement in the spinal cord. LBSL280 had the most
abnormal MRI with also striking involvement of the thal-
amus and globus pallidus.
DARS2 Variants
Table 3 and table e-3, links.lww.com/NXG/A376, provide
details on DARS2 variants and corresponding constructed
yeast variants.
All patients were compound heterozygous confirmed by pa-
rental segregation analysis. None of the variant combinations
observed in groups 1 and 2 have been reported before.4 Only 1
patient in group 1 (LBSL294) and 3 patients in group 2
(LBSL291, LBSL289, and LBSL280) had a classic intron 2
splice site variant. In groups 1 and 2, 3 and 2 variants, re-
spectively, were observed causing a premature stop. The
c.492+2T>C variant occurred once in both groups. One variant
in group 2 (c.1A>C, p.?) altered the DARS2 start codon and
likely affects mtAspRS synthesis due to less efficient
initiation.17,18 There were 10 and 3 unique missense variants in
group 1 and group 2, respectively. Two missense variants oc-
curred twice. Patient LBSL280 had 3 DARS2 variants; the
predictions for the missense variant were not considered when
comparing groups 1 and 2, as it was present on an allele with an
upstream nonsense variant. The missense variants tended to
have worse predicted Russell scores for group 1 than for group
2, indicating more disruptive nature of the variants.
Effects of individual missense variants were assessed by ex-
amining interspecies conservation of affected residues, their
location on mtAspRS protein structure and possible relevance
with functional regions, and predicted structural effects by
free energy change (DDG) calculations (table e-3, links.lww.
com/NXG/A376). The DDG of almost all missense variants
significantly differs from zero, indicating that they cause
structural alterations that are likely pathogenic. Figure 3
shows the location of missense variants on the mtAspRS
crystal structure, onto which tRNAAsp and the aspartyl-
Figure 2 Prototype MRI for Group 2
In patient LBSL288 at age 1 year and 2 months,
the cerebral white matter is rarefied but not
cystic (FLAIR image in C). The directly periven-
tricular and directly subcortical rims are un-
affected (arrowheads in A), and themiddle blade
of the corpus callosum is affected, whereas the
inner and outer blades are spared (arrows in A).
There is no brainstem involvement (B). The area
directly adjacent to the rarefied white matter
shows restricted diffusion (diffusion-weighted
image in D, ADC map in E) and enhancement
after contrast (F). On follow-up MRI at 8 years,
rarefaction and cystic degeneration in white
matter is present (arrows in FLAIR images in G
and H). There is no spinal cord involvement (I).
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adenylate substrate have been complexed by homology mod-
eling. All missense variants hit regions involved in tRNAAsp
binding (Arg58Gly, Gly128Arg, Thr136Lys, Phe157Ile,
Arg179Cys, and Ser597Gly) or near the catalytic region as
suggested by their proximity to the bound aspartyl-adenylate
(Leu250Val, Ala262Val, Val481Met, Phe484Leu, Leu588Val,
and Ser597Gly) and/or the homodimerization interface
(Arg179Cys, Leu250Val, Ala262Val, and Lys606Met). Group
1 variants occur close to or within the tRNAAsp binding region
or have a considerable structural effect near the aspartyl-
adenylate binding site (table e-3, links.lww.com/NXG/A376).
By contrast, the predicted effects of group 2 variants are less
severe. The Leu588Val variant is predicted to decrease stability
of the local protein structure, which may affect the nearby
aspartyl-adenylate binding site. Nevertheless, the leucine to
valine amino acid change is quite conservative and the protein
may preserve its main fold and function. The Lys606Met re-
placement may produce a hydrophobic interaction with
Leu215 and stabilize the formation of mtAspRS homodimers
that are important for tRNA synthetase activity.
Table 3 Mutations
LBSL nr DARS2 variant Amino acid change





























a Variants seen before in different combination, Van Berge et al.4
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Functional Studies in Yeast
We investigated the functional consequences of missense
variants on mitochondrial metabolism in yeast using the
DARS2 orthologous geneMSD1, in which a wild-type residue
has been substituted with the corresponding one found in
patients. Splice site, start codon, and nonsense variants were
not investigated.
Regarding the 6 missense variants affecting conserved resi-
dues (Leu250, Phe484, Ala262, Arg179, Ser597, and Lys606
corresponding to yLeu232, yPhe487, yAla244, yArg157,
ySer617, and yLys626, respectively), the yeast MSD1 codons
were directly mutated, producing the pathologic allele. For
the 4 variants affecting nonconserved residues located in an
otherwise conserved stretch (Arg58, Phe157, Val481, and
Leu588 corresponding to yLys42, yAla136, yIle484, and
yMet608, respectively), the yeast amino acid was replaced by
the human wild-type mtAspRS amino acid to serve as
humanized control. Subsequently, the variants were in-
troduced at these amino acids and results obtained with these
yeast strains were compared with their humanized controls.
The remaining 2 variants (Thr136 and Gly128, correspond-
ing to yAla115 and y-) were located in poorly conserved
regions and therefore not investigated.
The yeast mutant alleles and the humanized controls were
expressed in a yeast strain deleted of MSD1 (Δmsd1) that
failed to grow in medium containing oxidative carbon
sources. The ability to grow in the presence of respiratory
substrates (ethanol) at 28°C was first analyzed (data not
shown). The humanized MSD1 alleles (msd1Lys42Arg,
msd1Ile484Val, and msd1Met608Leu) rescued the absence of
MSD1. By contrast, the oxidative growth of both the hu-
manized msd1Ala136Phe allele and the corresponding mutant
msd1Phe136Ile was compromised and therefore not further
assessed.
Figure 3 Mapping of the Missense Variants on mtAspRS Structure
(A) Crystal structure of mtAspRS homodimer (PDB 4AH6; the mtAspRS monomers are in white and orange transparent ribbons) with the sites of missense
variants. The text color of each variant corresponds with the color of the variant depicted in the crystal structure. Red and blue triangles indicate missense
variants for group 1 and 2, respectively. (B) Close-up views around protein sites hit by themissensemtAspRS variants. Noncovalent interactions between the
affected amino acids and surrounding residues are indicated with dotted lines. mtAspRS protein is represented in its homodimeric form (monomers in
transparent white and orange ribbons) complexed with tRNAAsp (green) and aspartyl-adenosine-59-monophosphate (magenta).
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The oxidative growth ability of the strains expressing the
msd1Leu232Val, msd1Phe487Leu, msd1Arg157Cys, msd1Ser617Gly,
and msd1Leu608Val variants was severely affected, whereas the
msd1Ala244Val variant led to a mild reduction of growth. The
growth of the strains expressing msd1Arg42Gly, msd1Lys626Met,
and msd1Val484Met was similar to that of wild type. However,
incubation at 37°C revealed a severe growth defect for the
msd1Val484Met strain, indicating that a change in this position
affects mitochondrial function in yeast in a temperature-
sensitive manner.
Figure 4 (A) Normalized Respiration Activity in Wild-Type and Mutant MSD1 Strains
Cells were grown at 28°C in SC me-
dium without tryptophan supple-
mented with 0.6% glucose. Values
were normalized to the MSD1 wild-
type strain and represented as the
mean of at least three values ±SD. (B)
Normalized MSD1 protein levels in
wild-type and mutant MSD1 strains.
Msd1-HA protein levels were de-
termined with Western blot and nor-
malized to Por1 levels. TheMSD1:Por1
ratios were normalized to the ratio
found in the wild-type strain. Analysis
was performed on 3 independent
clones for each strain at 28°C. Graphs
show average ± SD. Statistical analysis
was performed using analysis of vari-
ance with Bonferroni correction **p <
0.01, *p < 0.05. Blue bars indicate hu-
manized alleles. MSD1, wild-type;
pFL39, empty vector. From left to right




to the human mutations Arg58Gly,
Leu250Val, Phe484Leu, Ala262Val,
Arg179Cys, Ser597Gly, and Val481-
Met, respectively. From left to right in
group 2, yMet608Leu/yLeu608Val and
yLys626Met correspond to human
mutations Leu588Val and Lys606Met,
respectively.
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To further investigate the effect of variants on oxidative
phosphorylation, the respiratory activity was measured (figure
4A). In agreement with the oxidative growth phenotype, the
strains expressingmsd1Leu232Val,msd1Phe487Leu,msd1Arg157Cys,
msd1Ser617Gly, and msd1Leu608Val were unable to consume
oxygen like the null Δmsd1mutant, whereas the expression of
the msd1Ala244Val allele induced a ;40% reduction of the re-
spiratory rate compared with the wild-type strain.
Although not displaying reduced oxidative growth,
msd1Lys626Met, msd1Val484Met, and msd1Arg42Gly did reveal a
reduction of oxygen consumption (;25%, 15%, and 20%,
respectively). The msd1Val484Met mutant also displayed a se-
vere respiratory rate defect at 37°C (data not shown), which
was in accordance with the observed growth defect.
Western blot analysis (figure 4B) showed decreased level of
the mutant protein expressed by msd1Phe487Leu (;50%) and
msd1Leu608Val (;40%), suggesting that for these mutants, the
mitochondrial defect could be due to protein instability. For 3
mutants, msd1Arg157Cys, msd1Ser617Gly, and msd1Lys626Met, the
results obtained demonstrated a significant protein level in-
crease (4-, 5-, and 2-fold, respectively) compared with wild
type. Because the corresponding mRNA level was similar to
that of the wild type (data not shown), the difference in
protein accumulation is not easily explained by increased gene
expression, but is more likely due to increased protein stability
and/or increased levels of protein synthesis. For the 4 other
variants (msd1Arg42Gly, msd1Leu232Val, msd1Ala244Val, and
msd1Val484Met), no differences in protein accumulation were
observed. Despite increased or normal Msd1 expression, the
mutant Msd1 proteins were incapable of supporting mito-
chondrial respiration activity.
Discussion
We describe 2 groups of patients with LBSL with MRI pat-
terns distinct from the known LBSL pattern. Patients with
classic LBSL with childhood to adult onset almost invariably
display distinctive brain stem and spinal cord tract abnor-
malities on MRI. Neonatal- and early infantile-onset forms
have been described with MRIs still displaying the charac-
teristic brain stem and spinal cord tract involvement. We
further broaden the LBSL disease spectrum by describing
antenatal and early infantile onset with highly atypical MRI
findings. Patients in group 1 had profound microcephaly, lack
of development, and MRIs dominated by dramatic cerebral
hypoplasia and atrophy. Clinical features were more variable
in group 2; MRIs were dominated by cerebral white matter
abnormalities and often lacked the brainstem abnormalities
typical of LBSL.
Almost all patients with LBSL described until now have
compound heterozygous DARS2 variants, with 95% of the
cases having an intron 2 splice site variant.4 This variant is
leaky, leading to the production of some normal protein,
probably guaranteeing a reasonable remaining mtAspRS
function.2 Except for 4 patients, patients in groups 1 and 2
lacked such leaky splice site variant. The combination of
variants on both alleles probably determines the remaining
mtAspRS activity within each cell and predictions based on a
single variant would therefore be of limited value in predicting
disease severity. However, the observation of fewer intron 2
splice site variants and a lower Russell score in group 1 is in
line with the more severe phenotype compared with group 2.
All missense variants in group 1 examined by crystal structure
mapping were predicted to cause structural defects in crucial
functional regions (e.g., catalytic and/or tRNAAsp binding
regions). Some variants observed in group 1 (e.g., Arg58Gly
and Gly128Arg) were associated with minor negative ΔΔG
values, although it must be considered that the calculations
did not take protein-bound ligands into account. Therefore,
their severe effect in patients can be the consequence of an
altered affinity for the tRNAAsp ligand. Variants in group 2
were predicted to have less severe effects on ligand binding or
protein structure than the variants in group 1.
Thus, the genetic and structural analyses suggest that the 2
different phenotypic severities can be discriminated by the
presence of 2 heavily damaged alleles (group 1) and only 1
severely damaged allele plus an allele with a partially active
protein product (group 2, i.e., the missense variants
Leu588Val and Lys606Met and the splice site variants).
Comparing the effects of the variants of groups 1 and 2 on
yeast mitochondrial function, the results do not fully explain
the difference in phenotype. Variants from both groups re-
duce oxidative growth and respiratory chain activity severely,
moderately or mildly. Not all functional yeast results agree
with predictions from the structural analyses in human and
bacterial orthologs and phenotypes of the patients. For ex-
ample, the Leu588Val variant in group 2 shows severe effects
on function in yeast, whereas the predicted effects on protein
structure and the phenotype of the patients (LBSL288,
LBSL290, and LBSL297) suggest a less detrimental effect on
the protein function. The opposite holds true for the
Arg58Gly variant in group 1. This variant, occurring in a
stretch of poorly conserved amino acids, may havemild effects
on protein stability and mitochondrial function in yeast,
whereas in humans, the impact of this variant is severe based
on the phenotype of patients LBSL285 and LBSL286. These
discrepancies may be explained by differences in amino acid
composition and structure in these regions between the hu-
man, bacterial and yeast proteins influencing their sensitivity
to the variants.
The MRI findings have implications for understanding the
pathophysiology of LBSL. Because of the preferential long
tract involvement, primary axonal disease was already hy-
pothesized at disease definition.1 In vitro studies further
supported this hypothesis, revealing that intron 2 splice site
variants had a greater effect on exon 3 exclusion in neural
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cells than in non-neural cells, and a greater effect for neu-
ronal cells than glial cells.19 In addition, correct inclusion of
exon 3 in the normal mtAspRS mRNA occurred less effi-
ciently in neural cells than non-neural cells, and this effect
was again more pronounced in neuronal cells than glial
cells.19 The combined effects may explain the selective
vulnerability of axonal tracts in LBSL. In 2 group 1 patients,
diffuse cerebral cortex diffusion restriction was docu-
mented, before development of profound cerebral atrophy,
indicating massive neuronal cell death. Most likely, the
initial cerebral hypoplasia is already caused by neuronal cell
death during development; the hypoplasia is subsequently
superseded by almost total atrophy. It remains unclear why
cerebral cortex neurons are specifically vulnerable and
neurons in the basal nuclei, thalami, and cerebellum are less
affected.
Neuronal and axonal vulnerability does not fully explain the
full LBSL disease spectrum. Diffusion restriction of the ce-
rebral cortex and severe cerebral atrophy are not observed in
group 2. A striking cerebral white matter disease is seen, but
the typical LBSL brain stem tract abnormalities are absent in
all patients but one, who is also otherwise exceptional. These
observations suggest that not all patients have predominant
axonal or neuronal disease.
Diffusion restriction in affected white matter structures is a
well-known feature of LBSL. Previous studies indicate that the
diffusion restriction is caused by intramyelinic water accu-
mulation and myelin microvacuolization, most likely caused
by glial pathology.20,21 It is typically seen in the periphery of
the abnormal white matter, not specifically in tracts, and the
location changes over time, indicating moving water com-
partments.20 In both groups 1 and 2, diffusion restriction in
affected white matter structures was observed. Lack of diffu-
sion restriction in the cerebral white matter on very early
MRIs, contrasting with the presence of diffusion restriction in
brain stem structures, is explained by the absence vs presence
of myelin at that early stage of brain development.
Recently, different TUBB4A variants were shown to cause
defects in different cell types (i.e., primary neuronal, primary
glial, or combined), correlating with specific clinical and MRI
phenotypes.22 The explanation for the different phenotypes
caused by different DARS2 variants may be similar. Two
conditional knockout mouse models were recently generated,
in which either neurons or oligodendrocytes were depleted of
mtAspRS. Cell-specific depletion was chosen because general
mtAspRS knockouts are not viable.23,24 Mitochondrial dys-
function and subsequently massive apoptosis occurred soon
after neuron-specific mtAspRS depletion.23 Of interest,
oligodendrocyte-specific mtAspRS depletion led to mito-
chondrial dysfunction but not apoptosis.23 These findings
indicate that cell-specific mtAspRS depletion results in dif-
ferent outcomes.
In group 1, we therefore hypothesize predominant neuronal
pathology, leading to cerebral cortex degeneration and severe
atrophy, with a component of glial pathology, leading to dif-
fusion restriction in white matter structures. In group 2, we
hypothesize predominant glial pathology, leading to cerebral
white matter disease with diffusion restriction, whereas neu-
ronal and axonal pathology is less clear and involvement of
brainstem tracts is exceptional, although we cannot exclude
that the typical brainstem abnormalities develop later and
were missed due to lack of longer MRI follow-up. Two pa-
tients indicate considerable variation within the groups. Pa-
tient LBSL284 had evident cerebral atrophy, although less
dramatic than other patients in group 1, but lacked white matter
abnormalities on MRI. Patient LBSL280 was the only patient in
group 2 with evident brainstem tract involvement, while also
having severe cerebral white matter, thalamus, and basal ganglia
abnormalities. These patients stress that variants may indeed
have a more variable, milder, or mixed cell-type effect.
Finally, the numerous tortuous vessels at the brain surface in
early disease stages in group 1 require some discussion. We
are unaware of a noncanonical function of mtAspRS affecting
neovascularization. Secondary neovascularization may be
more likely and is perhaps related to the dramatic cortical
neuronal cell death or profound energy deficiency related to
cortical mitochondrial dysfunction and energy depletion. In
MoyaMoya disease, for example, the ongoing ischemia has
been reported to cause overexpression of proangiogenic fac-
tors.25 A similar appearance of the cerebral arteries is seen in
Menkes disease,26 characterized by subacute cerebral cortex
degeneration and profound atrophy,27 and of the cerebellar
arteries in NUBPL variants, characterized by subacute cere-
bellar cortex degeneration and severe atrophy28; both disor-
ders are related to mitochondrial dysfunction.
In conclusion, this study expands the knowledge of the phe-
notypic spectrum caused by biallelic pathogenic DARS2 var-
iants, which are typically associated with a relatively mild
leukodystrophy and characteristic long tract abnormalities on
MRI. New are 2 early-onset severe phenotypes associated
either with profound cerebral atrophy or with a severe leu-
kodystrophy without long tract involvement. We found that
most related DARS2 variants likely impair mtAspRS expres-
sion or its interactions with ligands. Missense variants were
modeled in yeast and shown to affect mitochondrial function.
We observed some association between location of variants in
specific mtAspRS subdomains or residual mitochondrial
function and patients’ phenotypes (groups 1 and 2). Although
there is evidence of axonal disease in classic LBSL, severe
cerebral atrophy in group 1 points at neuronal apoptosis, both
involving the same cell type. Severe leukodystrophy without
atrophy and without long tract involvement in group 2 points
at primary glial pathology. The underlying mechanisms of
differentDARS2 variants leading to either dominant neuronal
or dominant glial pathology need further investigation.
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